Vanguard Group’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-1,252,358
Closed -$74.9M 4127
2020
Q2
$74.9M Buy
1,252,358
+107,708
+9% +$6.65M ﹤0.01% 1807
2020
Q1
$68M Buy
1,144,650
+21,316
+2% +$1.24M ﹤0.01% 1716
2019
Q4
$61.5M Buy
1,123,334
+445,201
+66% +$16.6M ﹤0.01% 2002
2019
Q3
$19.2M Buy
678,133
+103,271
+18% +$3.79M ﹤0.01% 2511
2019
Q2
$19.1M Buy
574,862
+284,762
+98% +$8.89M ﹤0.01% 2531
2019
Q1
$9.86M Buy
290,100
+75,092
+35% +$2.39M ﹤0.01% 2831
2018
Q4
$5.89M Buy
215,008
+121,065
+129% +$3.12M ﹤0.01% 3014
2018
Q3
$2.75M Buy
+93,943
New +$2.65M ﹤0.01% 3427

Other funds holding PRNB

Vanguard Group's PRNB Position: Q3 2020 in Review

Vanguard Group sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q3 2020, closing a stake of 1,252,358 shares — an estimated $74.9M sold.

Vanguard Group first reported a position in PRNB in Q3 2018 and held it in 8 quarters. The position peaked at $74.9M in Q2 2020. 9 funds tracked by Wall St. Rank hold PRNB as of Q3 2020.

  • Vanguard Group reported no remaining Principia Biopharma Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Vanguard Group sold 1,252,358 Principia Biopharma Inc. Common Stock shares in Q3 2020, an estimated $74.9M.
  • Vanguard Group first reported a position in Principia Biopharma Inc. Common Stock in Q3 2018 and held it in 8 quarters.
  • Vanguard Group's Principia Biopharma Inc. Common Stock position peaked at $74.9M in Q2 2020.
  • 9 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q3 2020.

Based on Vanguard Group's 13F filing for Q3 2020, filed 16 Nov 2020.